Compare PHIN & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHIN | QURE |
|---|---|---|
| Founded | 2023 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.2B |
| IPO Year | 2023 | 2013 |
| Metric | PHIN | QURE |
|---|---|---|
| Price | $71.59 | $48.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $70.00 | $45.00 |
| AVG Volume (30 Days) | 359.6K | ★ 1.3M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | ★ 84.09 | 29.67 |
| EPS | ★ 2.01 | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $6.35 | $126.12 |
| Revenue Next Year | $2.29 | $200.43 |
| P/E Ratio | $36.47 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $50.80 | $8.73 |
| 52 Week High | $86.94 | $71.50 |
| Indicator | PHIN | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 39.12 | 62.59 |
| Support Level | $70.54 | $39.50 |
| Resistance Level | $74.68 | $50.47 |
| Average True Range (ATR) | 2.03 | 1.93 |
| MACD | -0.25 | 0.22 |
| Stochastic Oscillator | 0.00 | 82.41 |
Phinia Inc is engaged in the development, design, and manufacture of integrated components and systems that optimize performance, increase efficiency, and reduce emissions in combustion and hybrid propulsion for commercial vehicles, industrial applications, and light vehicles. Its product portfolio includes alternative fuel systems, fuel delivery modules, evaporative canisters, diesel fuel injection systems, electrical systems, hydrogen solutions, associated software, and others. The company's reportable segments are; the Fuel Systems segment, which derives key revenue, and the Aftermarket segment. Geographically, it generates maximum revenue from the United States and the rest from the United Kingdom, China, Poland, Romania, Brazil, and other regions.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.